Genentech has its headquarters in South San Francisco, California, and other locations dedicated to manufacturing operations.
South San Francisco, California
| Since its founding in 1976, Genentech has made its headquarters in South San Francisco, California. Starting with one rented building and two staff members, the company's South San Francisco site has grown to a full campus with multiple buildings. Today, the South San Francisco site is home to a research center, manufacturing operations and various business functions. To learn more about Genentech, see the company's fact sheet and corporate backgrounder. |  |
 |
Vacaville, California
|
Genentech's Vacaville, California, site is located on 100 acres in Solano County, approximately 50 miles northeast of San Francisco. Acquired in 1994, it was first licensed to produce a biologic in 2000. The site houses manufacturing operations as well as quality and administrative services. Currently, the Vacaville facility is undergoing a major expansion. When it is completed, the Vacaville operation will be the largest biotechnology manufacturing plant of its kind in the world.
Read more about Genentech's Vacaville product operations in the backgrounder and timeline. |
|
 |
Oceanside, California
| The first facility of Genentech's Oceanside, California, location was purchased in June 2005. The state-of-the-art commercial and clinical biologics manufacturing facilities are located on 60 acres about 35 miles north of San Diego. Upon U.S. Food and Drug Administration (FDA) licensure in April 2007, the Oceanside facility added 90,000 liters of capacity that are initially dedicated to producing Avastin bulk drug substance. | |
 |
Hillsboro, Oregon
|
In 2006, Genentech purchased a 75-acre property 20 miles west of Portland in Hillsboro, Oregon, for the construction and development of a new state-of-the-art fill/finish facility. Genentech broke ground on the facility in December 2006. The new Oregon site is expected to be licensed and operational in 2010 and to employ approximately 300 employees by 2015.
The Hillsboro site is also the location for a new west coast warehouse and distribution center and was operational in July 2008. |
|
 |
Singapore
| In November 2006, Genentech and Lonza entered into a supply agreement for the manufacture of Avastin at Lonza's facility currently under construction in Singapore. Genentech has an option to purchase the facility before 2012. When completed, the 80,000-liter facility will be the first large-scale bulk biologics manufacturing plant in Singapore, with FDA licensure expected in 2010. Separately, in March 2007, Genentech entered into a long-term land-lease agreement in Singapore for the construction and development of a 1,000-liter E. coli manufacturing facility for the production of Lucentis bulk drug substance. Construction began in June 2007, and licensure is anticipated by early 2010. | |
 |